BillionToOne, Inc. Class A Common Stock (BLLN)vsIDEXX Laboratories Inc (IDXX)
BLLN
BillionToOne, Inc. Class A Common Stock
$97.19
-7.08%
HEALTHCARE · Cap: $4.52B
IDXX
IDEXX Laboratories Inc
$562.16
-0.46%
HEALTHCARE · Cap: $44.24B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 1154% more annual revenue ($4.45B vs $354.54M). IDXX leads profitability with a 24.6% profit margin vs 7.0%. IDXX trades at a lower P/E of 41.3x. IDXX earns a higher WallStSmart Score of 63/100 (C+).
BLLN
Hold40
out of 100
Grade: F
IDXX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLLN.
Margin of Safety
-53.1%
Fair Value
$423.77
Current Price
$562.16
$138.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 83.8% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 70 in profit
Strong operational efficiency at 31.8%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Areas to Watch
Trading at 8.8x book value
0.0% earnings growth
ROE of 5.0% — below average capital efficiency
7.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth, Debt/Equity. Revenue growth of 83.8% demonstrates continued momentum.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bear Case : BLLN
The primary concerns for BLLN are Price/Book, EPS Growth, Return on Equity. A P/E of 182.2x leaves little room for execution misses.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while IDXX is a mature play — different risk/reward profiles.
BLLN is growing revenue faster at 83.8% — sustainability is the question.
IDXX generates stronger free cash flow (234M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IDXX scores higher overall (63/100 vs 40/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?